Trials / Completed
CompletedNCT03711435
Traditional Chinese Medicine(TCM) Syndrome Classification of Idiopathic Pulmonary Fibrosis(IPF) and Metabolomics
Study on TCM Syndrome Classification of Idiopathic Pulmonary Fibrosis Based on Metabolomics
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (actual)
- Sponsor
- Xuzhou Traditional Chinese Medicine Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The pathogenesis of idiopathic pulmonary interstitial fibrosis is complex, and there is no specific biomarkers, the treatment effect is not such useful. Currently, it is discovered that Chinese medicine treatment may be effective. The investigators select patients with idiopathic pulmonary interstitial fibrosis and healthy controls, use metabolomics to study the biological characteristics of idiopathic pulmonary interstitial fibrosis, screen biomarkers of IPF, and label different TCM syndromes of IPF, explore the biological nature of IPF TCM syndromes, find the biological changes that occur during the development and progression of IPF and explore the metabolite marker clusters of IPF. Furthermore, the results of this study may find its diagnostic significance for IPF and Looking for potential targets for future treatment of IPF.
Conditions
Timeline
- Start date
- 2018-10-20
- Primary completion
- 2020-02-05
- Completion
- 2020-02-05
- First posted
- 2018-10-18
- Last updated
- 2022-07-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03711435. Inclusion in this directory is not an endorsement.